The Therapeutic Potential of Dihydroartemisinin in Cancer Treatment

Hu Zhou, Shuai Zhang, Ji-Hua Zhao, Meihua Gong, Dan Miao, Wei Xiong, Jiaying Guo, Yu Shi, Yumao JiangSSRN 2025 · DOI

TL;DR

This review highlights dihydroartemisinin (DHA), a derivative of the antimalarial drug artemisinin, as a potent natural compound with significant anticancer properties. It explores DHA's multifaceted mechanisms of action, including inhibiting tumor growth, inducing cell death, and preventing metastasis, and discusses innovative strategies to enhance its therapeutic efficacy for cancer treatment.

What Problem Does This Paper Address?

Cancer remains a leading global health challenge, characterized by tumor heterogeneity, drug resistance, metastasis, and severe side effects from current treatments. While targeted therapies and immunotherapies have shown promise, limitations persist. Natural products, with their multitarget mechanisms and favorable toxicity profiles, offer a promising avenue for novel anticancer drug development. This paper addresses the need for effective and safer cancer therapies by investigating the therapeutic potential of dihydroartemisinin (DHA), a derivative of artemisinin, which has demonstrated significant anticancer activity.

Methods

This paper is a comprehensive review, not an experimental study. Therefore, it does not present novel methods or algorithms. Instead, it systematically examines and synthesizes existing research on DHA's anticancer mechanisms and clinical potential. The authors draw upon preclinical and clinical evidence from numerous studies to provide a detailed overview of DHA's effects.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • Multifaceted Anticancer Mechanisms: DHA doesn't just kill cancer cells; it targets multiple processes crucial for tumor survival and progression. This includes inhibiting cell proliferation by interfering with the cell cycle, inducing various forms of programmed cell death (apoptosis, ferroptosis, pyroptosis, autophagic death), suppressing tumor invasion and migration, inhibiting angiogenesis (the formation of new blood vessels that feed tumors), and reprogramming tumor energy metabolism.
  • Dual Nature of Ferroptosis: DHA's ability to induce ferroptosis is a double-edged sword. While it can kill cancer cells, it can also lead to treatment resistance. Understanding and overcoming this resistance is a key area for future research.
  • Immunomodulatory Effects: DHA can enhance the body's own immune response against cancer by inducing immunogenic cell death (ICD) and modulating the tumor microenvironment to be less immunosuppressive. This opens doors for combination therapies with immunotherapies.
  • Overcoming Drug Resistance: DHA shows promise in reversing drug resistance to existing chemotherapy agents, making them more effective.
  • Hybridization and Delivery Systems: DHA's low bioavailability and poor solubility are significant clinical limitations. Strategies like molecular hybridization (combining DHA with other active molecules) and advanced drug delivery systems (liposomes, nanoparticles) are crucial for improving its therapeutic efficacy and safety.

Key Results

The paper details numerous preclinical findings demonstrating DHA's efficacy across various cancer types. While specific quantitative results are not the focus of a review, the paper consistently reports:

  • Inhibition of Tumor Proliferation: DHA induces cell cycle arrest (G1/S and G2/M phases) in various cancer cells.
  • Induction of Cell Death: DHA triggers apoptosis, ferroptosis, pyroptosis, and autophagic cell death through multiple pathways.
  • Suppression of Metastasis: DHA inhibits epithelial-mesenchymal transition (EMT), reduces matrix metalloproteinase (MMP) activity, and targets pathways involved in invasion and migration.
  • Inhibition of Angiogenesis: DHA blocks the formation of new blood vessels that feed tumors by targeting key signaling pathways like VEGF.
  • Modulation of Tumor Microenvironment: DHA can reduce immunosuppression and enhance anti-tumor immunity.
  • Improved Efficacy in Combination Therapies: DHA demonstrates synergistic effects when combined with chemotherapy, radiotherapy, and immunotherapy, often leading to enhanced anticancer activity and reduced toxicity.

Limitations and Future Work

  • Limited Clinical Translation: Despite promising preclinical data, clinical trials specifically testing DHA for cancer indications are still in their early stages.
  • Unclear Molecular Targets: While DHA's effects are well-documented, its precise molecular targets and mechanisms of action are not fully elucidated. Advanced methodologies are needed to identify these.
  • Pharmacokinetic Challenges: DHA's low bioavailability, poor solubility, and short half-life necessitate the development of advanced drug delivery systems and molecular hybridization strategies.
  • Interspecies Metabolic Variation: The metabolic profile of DHA varies significantly between species, highlighting the need for more human-relevant model systems.
  • Ferroptosis Resistance: Overcoming ferroptosis resistance and understanding its role in treatment resistance and metastasis are critical areas for future research.
  • Chronic Toxicity and Drug Interactions: Rigorous chronic toxicology studies and drug interaction evaluations are needed to ensure the safe clinical application of DHA.
  • Tumor-Specific Mechanisms: Future research should focus on tumor-specific mechanisms of DHA action, especially considering the ubiquitous presence of pathways like TGF-β.
  • Chemoprevention Potential: DHA's potential role in preventing early carcinogenic processes warrants further investigation.

The authors emphasize the need for interdisciplinary collaboration and rigorously designed clinical trials to fully validate DHA's therapeutic value and optimize its use in comprehensive cancer treatment.

Summary updated

BibTeX
@misc{zhou2025therapeutic,
  author = {Hu Zhou and Shuai Zhang and Ji-Hua Zhao and Meihua Gong and Dan Miao and Wei Xiong and Jiaying Guo and Yu Shi and Yumao Jiang},
  title = {{The Therapeutic Potential of Dihydroartemisinin in Cancer Treatment}},
  year = {2025},
  doi = {10.2139/ssrn.5733233},
  howpublished = {SSRN},
}
Figure